Another meta-analysis compared the efficacy of PD-1 and PD-L1 inhibitors in treating NSCLC and concluded that the tumor response rate was higher in the anti-PD-1 group than in the anti-PD-L1 group [10]. This evidence concerns the gene PDCD1 and neoplasm.